Delving into the Latest Updates on CS-060380 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CS 060380, CS060380

Target

THR-β

Action

agonists

Mechanism

THR-β agonists(Thyroid hormone receptor beta agonists)

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Nonalcoholic SteatohepatitisHyper LDL cholesterolaemiaHomozygous familial hypercholesterolemia

Inactive Indication-

Originator Organization

Cascade Pharmaceuticals, Inc.

Active Organization

Cascade Pharmaceuticals, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：初步评价 CS060380 片治疗非酒精性脂肪性肝炎（NASH）的有效性；次要目的：评价 CS060380 片治疗 NASH 的安全性和耐受性；评估 CS060380 片在 NASH 患者中的药代动力学/药效动力（PK/PD）特征；探索性目的：探索 CS060380 片对改善 NASH 患者的纤维化等相关生物标志物的影响；

[Translation]

Primary Objective: To preliminarily evaluate the efficacy of CS060380 tablets in the treatment of nonalcoholic steatohepatitis (NASH); Secondary Objective: To evaluate the safety and tolerability of CS060380 tablets in the treatment of NASH; and to assess the pharmacokinetic/pharmacodynamic (PK/PD) profile of CS060380 tablets in patients with NASH; Exploratory Objective: To explore the effect of CS060380 tablets on improving fibrosis and other related biomarkers in patients with NASH;

Start Date-

Sponsor / Collaborator

Cascade Pharmaceuticals, Inc.

100 Clinical Results associated with CS-060380

Login to view more data

100 Translational Medicine associated with CS-060380

Login to view more data

100 Patents (Medical) associated with CS-060380

Login to view more data

100 Deals associated with CS-060380

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	Phase 2	China	Cascade Pharmaceuticals, Inc.	09 Sep 2025
Hyper LDL cholesterolaemia	Phase 1	China	Cascade Pharmaceuticals, Inc.	03 Sep 2024
Homozygous familial hypercholesterolemia	IND Approval	China	Cascade Pharmaceuticals, Inc.	26 Nov 2024